Detection and characterization of olmutinib reactive metabolites by LC–MS/MS: Elucidation of bioactivation pathways

Non-small-cell lung cancer

Gridelli, C., Rossi, A., Carbone, D. P., Guarize, J., Karachaliou, N., Mok, T. S. K., Petrella, F., Spaggiari, L., & Rosell, R. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.9 · Cited by 1,121 · see citing works

Non–Small Cell Lung Cancer

_, _. (2008) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2008.0021 · Cited by 737 · see citing works

Non–Small Cell Lung Cancer

Ettinger, D. S., Akerley, W., Bepler, G., Blum, M. G., Chang, A. C., Cheney, R. T., Chirieac, L. R., D’Amico, T. A., Demmy, T. L., Ganti, A. K., et al. (2010) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2010.0056 · Cited by 729 · see citing works

Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States

Stepan, A. F., Walker, D. P., Bauman, J. N., Price, D. A., Baillie, T. A., Kalgutkar, A. S. S., & Aleo, M. D. (2011) · Chemical Research in Toxicology · doi:10.1021/tx200168d · Cited by 711 · see citing works

A Comprehensive Listing of Bioactivation Pathways of Organic Functional Groups

Kalgutkar, A. S. S., Gardner, I. B., Obach, R. S., Shaffer, C. L., Callegari, E., Henne, K. R., Mutlib, A. E., Dalvie, D., Lee, J. S., Nakai, Y., et al. (2005) · Current Drug Metabolism · doi:10.2174/1389200054021799 · Cited by 623 · see citing works

Managing the challenge of chemically reactive metabolites in drug development

Park, B. K., Boobis, A. R., Clarke, S. E., Goldring, C. E., Jones, D., Kenna, J. G., Lambert, C., Laverty, H., Naisbitt, D. J., Nelson, S. D., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3408 · Cited by 466 · see citing works

Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer

Tan, C., Gilligan, D., & Pacey, S. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00246-6 · Cited by 390 · see citing works

Idiosyncratic drug reactions: the reactive metabolite syndromes

Knowles, S. R., Uetrecht, J., & Shear, N. H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03137-8 · Cited by 331 · see citing works

Olmutinib: First Global Approval

Kim, E. S. (2016) · Drugs · doi:10.1007/s40265-016-0606-z · Cited by 170 · see citing works

Mechanism of Idiosyncratic Drug Reactions: Reactive Metabolites Formation, Protein Binding and the Regulation of the Immune System

Ju, C. H., & Uetrecht, J. (2002) · Current Drug Metabolism · doi:10.2174/1389200023337333 · Cited by 166 · see citing works

Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions

Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155 · see citing works

Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry

Ma, S., & Subramanian, R. (2006) · Journal of Mass Spectrometry · doi:10.1002/jms.1098 · Cited by 154 · see citing works

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

Liao, B.-C., Lin, C., & Yang, J. C. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000164 · Cited by 147 · see citing works

Recent advances in applications of liquid chromatography–tandem mass spectrometry to the analysis of reactive drug metabolites

Ma, S., & Zhu, M. (2008) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2008.09.014 · Cited by 139 · see citing works

Liquid chromatography–mass spectrometry in in vitro drug metabolite screening

Tolonen, A., Turpeinen, M., & Pelkonen, O. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.002 · Cited by 137 · see citing works

The Role of Extrahepatic Metabolism in the Pharmacokinetics of the Targeted Covalent Inhibitors Afatinib, Ibrutinib, and Neratinib

Shibata, Y., & Chiba, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061424 · Cited by 112 · see citing works

The use of structural alerts to avoid the toxicity of pharmaceuticals

Limban, C., Nuță, D. C., Chiriţă, C., et al. (2018) · Toxicology Reports · doi:10.1016/j.toxrep.2018.08.017 · Cited by 108 · see citing works

Targeted Therapies for Lung Cancer

Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 103 · see citing works

The preparation of microsomes

von Jagow, R., Kampffmeyer, H. G., & Kinese, M. (1965) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/bf00245731 · Cited by 79 · see citing works

Role of Biotransformation Studies in Minimizing Metabolism-Related Liabilities in Drug Discovery

Shu, Y., Johnson, B. M., & Yang, T. J. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9016-9 · Cited by 74 · see citing works

Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship

Mašič, L. P. (2011) · Current Drug Metabolism · doi:10.2174/138920011794520044 · Cited by 71 · see citing works

Potential Metabolic Bioactivation Pathways Involving Cyclic Tertiary Amines and Azaarenes

Castagnoli, N. J., Rimoldi, J. M., Bloomquist, J., et al. (1997) · Chemical Research in Toxicology · doi:10.1021/tx970096j · Cited by 70 · see citing works

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer

Barnes, T. A., O'Kane, G. M., Vincent, M. D., & Leighl, N. B. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00113 · Cited by 61 · see citing works

In Vitro Bioactivation of Dihydrobenzoxathiin Selective Estrogen Receptor Modulators by Cytochrome P450 3A4 in Human Liver Microsomes: Formation of Reactive Iminium and Quinone Type Metabolites

Zhang, Z., Chen, Q., Li, Y., et al. (2005) · Chemical Research in Toxicology · doi:10.1021/tx0496789 · Cited by 59 · see citing works

Application of the margin of exposure (MoE) approach to substances in food that are genotoxic and carcinogenic

Coulet, M., Leblanc, J., & Setzer, R. W. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.10.018 · Cited by 56 · see citing works

Investigation of the metabolic stability of olmutinib by validated LC-MS/MS: quantification in human plasma

Attwa, M. W., Kadi, A. A., Darwish, H. W., & Abdelhameed, A. S. (2018) · RSC Advances · doi:10.1039/c8ra08161a · Cited by 45 · see citing works

Reactive intermediates and bioactivation pathways characterization of avitinib by LC–MS/MS: In vitro metabolic investigation

Attwa, M. W., Kadi, A. A., & Abdelhameed, A. S. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.11.033 · Cited by 44 · see citing works

LC–MS/MS reveals the formation of iminium and quinone methide reactive intermediates in entrectinib metabolism: In vivo and in vitro metabolic investigation

Attwa, M. W., Kadi, A. A., Alrabiah, H. K., et al. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.07.032 · Cited by 43 · see citing works

BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D.

Park, K., Lee, J.-S., Lee, K. H., Kim, J.-H., Cho, B. C., Min, Y. J., Choi, Y., Han, J., Kim, B.-S., Kim, J.-S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9055 · Cited by 43 · see citing works

Identification and characterization of in vivo, in vitro and reactive metabolites of vandetanib using LC–ESI–MS/MS

Attwa, M. W., Kadi, A. A., Darwish, H. W., et al. (2018) · Chemistry Central Journal · doi:10.1186/s13065-018-0467-5 · Cited by 43 · see citing works

Identification and characterization of in vitro phase I and reactive metabolites of masitinib using a LC-MS/MS method: bioactivation pathway elucidation

Amer, S. M., Kadi, A. A., Darwish, H. W., et al. (2017) · RSC Advances · doi:10.1039/c6ra25767d · Cited by 41 · see citing works

Proposed mechanisms for the fragmentation of doubly allylic alkenamides (tingle compounds) by low energy collisional activation in a triple quadrupole mass spectrometer

Hiserodt, R. D., Pope, B. M., Cossette, M., et al. (2004) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2004.06.009 · Cited by 37 · see citing works

LC-MS/MS reveals the formation of reactive ortho -quinone and iminium intermediates in saracatinib metabolism: Phase I metabolic profiling

Attwa, M. W., Kadi, A. A., Darwish, H. W., & Alrabiah, H. K. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.03.037 · Cited by 37 · see citing works

Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways

Kadi, A. A., Darwish, H. W., Attwa, M. W., et al. (2016) · RSC Advances · doi:10.1039/c6ra09985h · Cited by 37 · see citing works

Liquid chromatography tandem mass spectrometry method for the quantification of vandetanib in human plasma and rat liver microsomes matrices: metabolic stability investigation

Amer, S. M., Kadi, A. A., Darwish, H. W., et al. (2017) · Chemistry Central Journal · doi:10.1186/s13065-017-0274-4 · Cited by 36 · see citing works

LC-ESI-MS/MS reveals the formation of reactive intermediates in brigatinib metabolism: elucidation of bioactivation pathways

Kadi, A. A., Attwa, M. W., & Darwish, H. W. (2018) · RSC Advances · doi:10.1039/c7ra10533a · Cited by 35 · see citing works

LC-MS/MS reveals the formation of aldehydes and iminium reactive intermediates in foretinib metabolism: phase I metabolic profiling

Kadi, A. A., Amer, S. M., Darwish, H. W., et al. (2017) · RSC Advances · doi:10.1039/c7ra06341e · Cited by 33 · see citing works

Application of the Margin of Exposure (MoE) approach to substances in food that are genotoxic and carcinogenic

Bolger, P. M., Leblanc, J., & Setzer, R. W. (2010) · Food and Chemical Toxicology · doi:10.1016/j.fct.2009.11.040 · Cited by 33 · see citing works

Identification of Novel Pathways in Idelalisib Metabolism and Bioactivation

Zhu, J., Wang, P., Shehu, A. I., Lu, J. L., Bi, H., & Ma, X. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00023 · Cited by 31 · see citing works

Liquid chromatography–tandem mass spectrometry method for simultaneous determination of cyclosporine A and its three metabolites AM1, AM9 and AM4N in whole blood and isolated lymphocytes in renal transplant patients

Brozmanová, H., Perinova, I., Halvová, P., et al. (2010) · Journal of Separation Science · doi:10.1002/jssc.201000185 · Cited by 22 · see citing works

Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway

Li, A. C., Yu, E., Ring, S. C., et al. (2013) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.6758 · Cited by 19 · see citing works

Metabolic activation routes of arylamines and their genotoxic effects.

Meerman, J. H. N., & van de Poll, M. L. (1994) · Environmental Health Perspectives · doi:10.1289/ehp.94102s6153 · Cited by 16 · see citing works

Correction: Detection and characterization of ponatinib reactive metabolites by liquid chromatography tandem mass spectrometry and elucidation of bioactivation pathways

Kadi, A. A., Darwish, H. W., Attwa, M. W., et al. (2017) · RSC Advances · doi:10.1039/c7ra90020a · Cited by 14 · see citing works

Hydrogen rearrangement and ring cleavage reactions study of progesterone by triple quadrupole mass spectrometry and density functional theory

Jeilani, Y. A., Cardelino, B. H., & Ibeanusi, V. M. (2011) · Journal of Mass Spectrometry · doi:10.1002/jms.1931 · Cited by 12 · see citing works

Identification and quantification of 34 drugs and toxic compounds in blood, urine, and gastric content using liquid chromatography with tandem mass spectrometry

Liang, C., Ye, H., Wang, R., et al. (2015) · Journal of Separation Science · doi:10.1002/jssc.201401300 · Cited by 8 · see citing works

Analysis of eflucimibe and related impurities by highly sensitive liquid chromatography‐electrospray‐tandem mass spectrometry

Mesplet, N., Morin, P., & Ribet, J. (2003) · Journal of Separation Science · doi:10.1002/jssc.200301551 · Cited by 3 · see citing works

P3.02b-126 Clinical Activity of Olmutinib (HM61713) Used on a Compassionate IND Basis for Patients with Lung Adenocarcinoma (LADC) in Korea

Lee, J. S., Han, J., Lee, Y., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.1794 · Cited by 3 · see citing works

Metabolic Activation Routes of Arylamines and Their Genotoxic Effects

Meerman, J. H. N., & van de Poll, M. L. M. (1994) · Environmental Health Perspectives · doi:10.2307/3432170 · Cited by 1 · see citing works

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

An Iminium Salt Organocatalyst for Selective Aliphatic C–H Hydroxylation

Wang, D., Shuler, W. G., Pierce, C. J., et al. (2016) · Organic Letters · doi:10.1021/acs.orglett.6b01832 · Cited by 37 · see citing works

Role of Cyclic Tertiary Amine Bioactivation to Reactive Iminium Species: Structure Toxicity Relationship

Mašič, L. P. (2011) · Current Drug Metabolism · doi:10.2174/138920011794520044 · Cited by 71 · see citing works

Evidence of two metabolic pathways for degradation of 2-methylphenanthrene by Sphingomonas sp. strain (2MPII)

Budzinski, H., Nadalig, T., Raymond, N., et al. (2000) · Environmental Toxicology and Chemistry · doi:10.1002/etc.5620191109 · Cited by 11 · see citing works

Structure of Reactive Intermediates of Organocatalysis

Seebàch, D., Groelj, U., Badine, D. M., et al. (2009) · Synfacts · doi:10.1055/s-0028-1087719

Reactive intermediates and bioactivation pathways characterization of avitinib by LC–MS/MS: In vitro metabolic investigation

Attwa, M. W., Kadi, A. A., & Abdelhameed, A. S. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.11.033 · Cited by 44 · see citing works